Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genmab ( (GMAB) ) has provided an announcement.
On January 29, 2026, Genmab A/S announced that its board had granted 32,806 restricted stock units and 34,307 warrants to employees of the company and its subsidiaries as part of its long-term incentive programs. The RSUs, each representing the conditional right to one Genmab share with a fair value equal to the January 29 closing price of DKK 2,067, will vest after three years subject to program conditions, while the cost-free warrants, also struck at DKK 2,067 per share and valued at DKK 658.81 using Black-Scholes, will vest after three years and remain exercisable until seven years from the grant date. The move underscores Genmab’s continued use of equity-based compensation to align employees with shareholder interests and support retention in a competitive global biotech talent market.
The most recent analyst rating on (GMAB) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance and positive earnings call sentiment are the primary drivers of its score. The company’s strategic initiatives and solid valuation further support its potential, despite some technical indicators suggesting caution.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is an international biotechnology company focused on developing innovative antibody-based medicines for cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, Denmark, the company has built a broad portfolio of therapeutic antibody formats, including bispecific antibodies, antibody–drug conjugates and immune‑modulating antibodies. Genmab’s science underpins eight approved antibody medicines and a strong late‑stage clinical pipeline, supported by an international presence across North America, Europe and Asia-Pacific.
Average Trading Volume: 1,764,723
Technical Sentiment Signal: Buy
Current Market Cap: $21.27B
For a thorough assessment of GMAB stock, go to TipRanks’ Stock Analysis page.